OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+22.24%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$386M
AUM Growth
+$386M
(+10%)
Cap. Flow
-$6.89M
Cap. Flow
% of AUM
-1.78%
Top 10 Holdings %
Top 10 Hldgs %
62.47%
Holding
49
New
11
Increased
11
Reduced
7
Closed
13
Top Buys
| 1 |
PTE
PolarityTE, Inc. Common Stock
PTE
|
$18.8M |
| 2 |
AMAG
AMAG Pharmaceuticals, Inc.
AMAG
|
$8.19M |
| 3 |
Viridian Therapeutics
VRDN
|
$7.69M |
| 4 |
Dianthus Therapeutics
DNTH
|
$7.43M |
| 5 |
Xencor
XNCR
|
$6.66M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$15.9M |
| 2 |
Axogen
AXGN
|
$13.8M |
| 3 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
$10.7M |
| 4 |
Ardelyx
ARDX
|
$5.73M |
| 5 |
ABLX
Ablynx NV American Depositary Shares
ABLX
|
$4.91M |
Sector Composition
| 1 | Healthcare | 97.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axogen
AXGN
$743M
| $72.4M | 18.73% | 1,440,000 -275,000 | -16% | -$13.8M |
|
|
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
| $30.4M | 7.86% | 175,000 -4,400 | -2% | -$763K |
|
3
Codexis
CDXS
$246M
| $25.2M | 6.52% | 1,750,000 +49,400 | +3% | +$711K |
|
4
FibroGen
FGEN
$47.8M
| $22.5M | 5.83% | 360,000 | – | – |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $22.2M | 5.75% | 350,000 -250,000 | -42% | -$15.9M |
|
|
PTE
6
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $18.8M | 4.87% | +800,000 | New | +$18.8M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $16.5M | 4.28% | 420,000 +55,000 | +15% | +$2.16M |
|
8
Viking Therapeutics
VKTX
$3.04B
| $11.4M | 2.95% | 1,200,000 +99,200 | +9% | +$941K |
|
|
SBBP
9
DELISTED
Strongbridge Biopharma plc.
SBBP
| $11M | 2.84% | 1,830,000 +240,000 | +15% | +$1.44M |
|
10
Agios Pharmaceuticals
AGIO
$2.19B
| $10.9M | 2.83% | 130,000 | – | – |
|
11
Fennec Pharmaceuticals
FENC
$247M
| $9.87M | 2.55% | 945,000 +72,000 | +8% | +$752K |
|
|
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
| $9.36M | 2.42% | 697,500 +32,500 | +5% | +$436K |
|
13
TG Therapeutics
TGTX
$4.65B
| $8.22M | 2.13% | 625,000 +350,800 | +128% | +$4.61M |
|
|
AMAG
14
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $8.19M | 2.12% | +420,000 | New | +$8.19M |
|
|
15
Viridian Therapeutics
VRDN
$1.5B
| $7.69M | 1.99% | +1,200,000 | New | +$7.69M |
|
16
Ocular Therapeutix
OCUL
$2.12B
| $7.5M | 1.94% | 1,111,000 | – | – |
|
|
17
Dianthus Therapeutics
DNTH
$759M
| $7.43M | 1.92% | +550,000 | New | +$7.43M |
|
|
BOLD
18
DELISTED
Audentes Therapeutics, Inc
BOLD
| $7.26M | 1.88% | 190,000 | – | – |
|
19
Sangamo Therapeutics
SGMO
$157M
| $7.17M | 1.86% | 505,000 -30,000 | -6% | -$426K |
|
20
Xoma
XOMA
$392M
| $6.69M | 1.73% | 320,200 | – | – |
|
|
21
Xencor
XNCR
$580M
| $6.66M | 1.72% | +180,000 | New | +$6.66M |
|
|
CORI
22
DELISTED
Corium International, Inc.
CORI
| $6.41M | 1.66% | 800,000 -265,000 | -25% | -$2.12M |
|
23
Cidara Therapeutics
CDTX
$1.66B
| $6.24M | 1.62% | +1,200,000 | New | +$6.24M |
|
24
Ultragenyx Pharmaceutical
RARE
$2.89B
| $6.15M | 1.59% | 80,000 | – | – |
|
25
PTC Therapeutics
PTCT
$3.92B
| $6.07M | 1.57% | 180,000 +35,000 | +24% | +$1.18M |
|